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Outcomes Measurement Information System
Gastrointestinal Symptom Scales in
Systemic Sclerosis
VIVEK NAGARAJA,1 RON D. HAYS,2 PUJA P. KHANNA,1 BRENNAN M. R. SPIEGEL,3 LIN CHANG,4
GIL Y. MELMED,5 ROGER BOLUS,6 AND DINESH KHANNA1
Objective. Gastrointestinal (GI) involvement is common in patients with systemic sclerosis (SSc; scleroderma). The
Patient-Reported Outcomes Measurement Information System (PROMIS) GI symptom item bank captures upper and
lower GI symptoms (reﬂux, disrupted swallowing, nausea/vomiting, belly pain, gas/bloating/ﬂatulence, diarrhea, consti-
pation, and fecal incontinence). The objective of this study was to evaluate the construct validity of the PROMIS GI bank
in SSc.
Methods. A total of 167 patients with SSc were administered the PROMIS GI bank and the University of California, Los
Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (GIT 2.0) instrument. GIT 2.0 is a multi-item
instrument that measures SSc-associated GI symptoms. Product-moment correlations and a multitrait–multimethod
analysis of the PROMIS GI scales with the GIT 2.0 symptom scales were used to evaluate convergent and discriminant
validity.
Results. Patients with SSc GI involvement had PROMIS GI scale scores 0.2–0.7 SD worse than the US general population.
Correlations among scales measuring the same domains for the PROMIS GI and GIT 2.0 measures were large, ranging
from 0.61 to 0.87 (average r  0.77). The average correlation between different symptom scales was 0.22, supporting
discriminant validity.
Conclusion. This study provides support for the construct validity of the PROMIS GI scales in SSc. Future research is
needed to assess the responsiveness to change of these scales in patients with SSc.
INTRODUCTION
Patient-reported outcomes (PROs) are widely used in re-
search and are playing an increasingly important role in
clinical practice (1). In a clinical practice, PROs can be
administered to identify presence/absence of symptoms or
assess symptom severity, which can assist in clinical de-
cision making (2). Unlike the traditional measures of dis-
ease burden (direct and indirect expenditures of a disease),
PRO instruments document the burden of disease in terms
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of impact on daily functioning and well-being, or health-
related quality of life (HRQOL) (3).
Gastrointestinal tract (GI) involvement occurs in ap-
proximately 90% of patients with systemic sclerosis (SSc;
scleroderma) (4,5) and is associated with decline in
HRQOL (6,7). The University of California, Los Angeles,
Scleroderma Clinical Trials Consortium Gastrointestinal
Scale (UCLA SCTC GIT 2.0 [GIT 2.0]) is a multi-item
instrument that measures GI symptoms and their impact
on HRQOL. Support for the reliability and validity (in-
cluding responsiveness to change) of the GIT 2.0 was
found in different observational cohorts (8–11). It is con-
sidered the “legacy” instrument to assess GI involvement
in patients with SSc (2).
The National Institutes of Health (NIH) funded the
Patient-Reported Outcomes Measurement Information
System (PROMIS; trademarked by the NIH) Roadmap ini-
tiative (available at www.nihpromis.org) to develop, eval-
uate, and standardize item banks to measure PROs across
patients with different medical conditions and in the US
general population (12,13). PROMIS GI symptom item
banks that assess 8 GI domains were recently developed
(14,15). The goal of PROMIS is to develop reliable and
valid item banks using item response theory (IRT) that
can be administered in a variety of formats, including
short forms and computerized adaptive tests (12,16,17).
PROMIS has several advantages over the traditional instru-
ments. First, a consistent qualitative process is employed
with detailed systematic review, focus groups, cognitive
interviews, and translatability for each item bank. Second,
PROMIS static items produce more reliable information
than existing measures, such as the Short Form 36 health
survey physical functioning component-10 and the Health
Assessment Questionnaire disability index (18).
The goal of this study was to evaluate the construct
validity of the PROMIS GI symptom scales.
MATERIALS AND METHODS
PRO measures. NIH PROMIS GI symptom item bank.
The GI symptom item banks were developed using the
standard PROMIS qualitative and quantitative methodol-
ogy (19). Brieﬂy, the qualitative aim was achieved through
completion of a systematic review of the literature to iden-
tify extant GI PRO items followed by a comprehensive
review and evaluation of these items (15). The individual
items from existing instruments were grouped based on
different symptoms. This was complemented by focus
group discussions of patients with GI conditions to eval-
uate their symptoms. New items were developed based on
extant items and input from the focus group participants,
followed by ﬁne tuning of itemwording based on cognitive
interviews with GI patients. The items were administered
to 865 patients with different GI disorders (including SSc)
at the following 4 centers in the US: University of Michi-
gan Hospital, UCLA Medical Center, Cedars Sinai Medical
Center, and VA West Los Angeles Medical Center, and to
1,177 individuals from the US general population. The US
general population was included to develop norms for
clinical care and research. Items were ﬁnalized based on
psychometric analyses, including categorical conﬁrmatory
factor analyses and IRT modeling (15).
The ﬁnal PROMIS GI symptom instrument (15) has 60
items and assesses 8 domains: gastroesophageal reﬂux (13
items), disrupted swallowing (7 items), diarrhea (5 items),
bowel incontinence/soilage (4 items), nausea and vomiting
(4 items), constipation (9 items), belly pain (6 items), and
gas/bloating/ﬂatulence (12 items). All scales were cali-
brated using the 2-parameter IRT graded response model
and scored on a T score metric with a mean  SD of 50 
10 in the US general population. A higher score denotes
more GI symptoms. The recall period for PROMIS GI
symptom items is 1 week.
GIT 2.0. The GIT 2.0 was developed to assess presence/
absence and severity of GI involvement and the conse-
quent impairment in social and emotional well-being in
patients with SSc (11). Previous work has provided sup-
port for the reliability and validity of the GIT 2.0 scales
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Signiﬁcance & Innovations
● Patient-reported outcomes play an important role
in clinical practice. They help to assess the disease
burden and guide treatment.
● The Patient-Reported Outcomes Measurement In-
formation System (PROMIS) instruments are more
precise than existing legacy measures.
● The newly developed PROMIS gastrointestinal
(GI) symptom item bank captures 8 GI-speciﬁc
symptom scales for luminal GI disorders.
● In patients with systemic sclerosis (SSc; sclero-
derma), PROMIS GI scales showed construct (con-
vergent and discriminant) validity relative to a
legacy instrument (University of California Los
Angeles Scleroderma Clinical Trials Consortium
gastrointestinal scale [GIT 2.0]).
● Compared to GIT 2.0, the PROMIS GI bank has
additional scales that are applicable to patients
with SSc.
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(11,20). The GIT 2.0 scales were found to be sensitive to
the presence of abnormalities on structural/motility test-
ing and can be routinely used as an initial screening test in
clinical practice (8). It is the “legacy” PRO measure to
assess the severity of GI involvement and its impact on
HRQOL in patients with SSc. The GIT 2.0 has 34 items; the
7 multi-item scales include reﬂux (8 items), distention/
bloating (4 items), diarrhea (2 items), fecal soilage (1 item),
constipation (4 items), emotional well-being (9 items), and
social functioning (6 items) (2). The reﬂux scale has 1 item
each for solid food dysphagia, nausea, and vomiting. The
items are scored from 0.0–3.0, except diarrhea (0.0–2.0)
and constipation (0.0–2.5). Higher values indicate worse
HRQOL. The total GIT 2.0 score averages 6 of 7 scales
(excluding constipation) and is scored from 0.0 (no GI
symptoms) to 2.8 (severe GI symptoms). The recall period
for the GIT 2.0 items is 1 week.
Participants. A total of 167 patients with SSc are a
subset of 865 patients who were recruited predominantly
at the University of Michigan Scleroderma Clinic. The
diagnosis of SSc was made based on the 1980 American
College of Rheumatology criteria (21) and/or clinical diag-
nosis by 2 physicians (PPK and DK). This subset of pa-
tients was administered the PROMIS GI symptom item
bank and GIT 2.0 instrument.
Statistical analysis. Descriptive statistics are presented
as means and SDs for continuous variables and percent-
ages for categorical variables. In addition to mean scores
and SDs, ranges and percentages of respondents scoring
the minimum and maximum possible scores were calcu-
lated to evaluate scale score distributions for the PROMIS
GI symptom and GIT 2.0 scales. Internal consistency reli-
ability for all scales was estimated using Cronbach’s alpha,
and reliability for the GIT 2.0 total score was estimated
using Mosier’s formula. Reliability 0.70 was considered
satisfactory for group comparisons (22).
Convergent and discriminant validity are 2 components
of construct validity. Convergent validity is supported
when different methods of assessing the same construct
(e.g., 2 measures of reﬂux) should be highly correlated.
Table 1. Baseline characteristics of the study
participants*
Variables
Total sample
(n  167)
Age, mean  SD (range) years 53  13 (22–80)
Women 91
Race/ethnicity
White 67
African American 11
Hispanic 10
Asian 7
Other 5
Education
 College education 2
Some college 16
College graduate 20
Graduate degree 63
Marital status
Married 65
Never married 10
Widowed/separated/divorced 25
Employment
Full time/part time 38
Retired 24
Unemployed 4
On disability 22
Homemaker 10
Full-time student 2
* Values are the percentage unless indicated otherwise.
Table 2. Descriptive statistics of PROMIS GI item band and UCLA SCTC GIT 2.0*
Scale Mean  SD
Minimum
score
Maximum
score
% with
minimum
% with
maximum Cronbach’s 
PROMIS GI symptom item bank
Reﬂux 54  8 33 75 1 1 0.83
Disrupted swallowing 56  10 41 83 14 1 0.91
Nausea/ vomiting 54  11 41 84 20 1 0.73
Belly pain 55  10 37 79 2 1 0.88
Gas/bloat/ﬂatulence 57  10 38 79 1 1 0.94
Diarrhea 55  11 40 82 1 1 0.89
Constipation 52  9 37 75 7 1 0.88
Fecal incontinence 54  13 44 91 47 1 0.90
UCLA SCTC GIT 2.0
Reﬂux 0.85  0.63 0.0 3.0 8 1 0.80
Distention/bloating 1.38  0.87 0.0 3.0 4 6 0.78
Diarrhea 0.65  0.70 0.0 2.0 45 9 0.72
Fecal soilage 0.47  0.81 0.0 3.0 69 4 NA
Constipation 0.61  0.59 0.0 2.5 26 1 0.74
Emotional well-being 0.66  0.74 0.0 3.0 27 1 0.90
Social functioning 0.52  0.58 0.0 2.33 34 1 0.78
Total GI score 0.75  0.51 0.0 2.34 1 0 0.92
* PROMIS  Patient-Reported Outcomes Measurement Information System; GI  gastrointestinal; UCLA SCTC GIT 2.0  University of California,
Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale; NA  not applicable.
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Pearson’s product-moment correlations of the PROMIS GI
symptom scales with corresponding GIT 2.0 scales were
used to assess convergent validity. Discriminant validity
is supported when measures of different constructs (e.g.,
diarrhea and constipation) do not correlate highly with
each other. We conducted multitrait, multimethod matrix
(MTMM) analyses to evaluate convergent and discrim-
inant validity (23). We hypothesized that correlations
among scales measuring the same construct would be sig-
niﬁcantly larger than other correlations (24). A coefﬁcient
of 0.50 was considered large for current analysis.
RESULTS
The majority of participants were female (91%), white
(54%), and highly educated (98% with some college de-
gree); the mean  SD age of the sample was 53  13 years
(Table 1).
Table 2 provides descriptive statistics and reliability
estimates for the PROMIS GI symptom and GIT 2.0 scales.
The PROMIS GI scale scores of patients in the sample were
0.2–0.7 SD worse than the US population. The percentage
of patients with minimum scores on the PROMIS scales
ranged from 1% (for reﬂux, bloating, and diarrhea scales)
to 47% (for fecal incontinence scale), while the percentage
with maximum scores was 1% for all scales. Cronbach’s
coefﬁcient alpha was 0.70 for all scales.
For GIT 2.0, the mean  SD scores ranged from 0.47 
0.81 for fecal soilage, to 1.38 0.87 for distension/bloating
scale. The percentage of patients with minimum scores
ranged from 4% (for distension/bloating scale) to 69%
(for fecal soilage scale), while the percentage with maxi-
mum scores ranged from 1% (for reﬂux, constipation, emo-
tional well-being, and social functioning scales) to 9%
(for diarrhea scale). Cronbach’s alpha was 0.70 for all
scales.
Pearson’s product-moment correlations between corre-
sponding scale scores were large (ranging from 0.61 to
0.87) (Table 3). GIT 2.0 does not have separate scales for
disrupted swallowing and nausea/vomiting. However,
Table 3. Product-moment correlations between PROMIS GI symptom item bank and UCLA SCTC GIT 2.0 symptom scales*
UCLA SCTC GIT 2.0
Reﬂux†
Distention/
bloating Diarrhea Constipation
Fecal
incontinence
PROMIS GI
Reﬂux 0.77‡ 0.44 0.13 0.25 0.03
Disrupted swallowing 0.61‡ 0.39 0.16 0.21 0.13
Nausea and vomiting 0.66‡ 0.44 0.20 0.22 0.18
Belly pain 0.45 0.49 0.23 0.34 0.04
Gas/bloating/ﬂatulence 0.46 0.73‡ 0.30 0.29 0.10
Diarrhea 0.25 0.25 0.65‡ 0.02 0.54
Constipation 0.37 0.32 0.05 0.76‡ 0.01
Fecal incontinence 0.12 0.11 0.43 0.18 0.87‡
* PROMIS  Patient-Reported Outcomes Measurement Information System; GI  gastrointestinal; UCLA SCTC GIT 2.0  University of California,
Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale.
† GIT 2.0 reﬂux scale asks about reﬂux, dysphagia to solid foods, and nausea/vomiting.
‡ Hypothesized correlation coefﬁcients.
Table 4. Multitrait, multimethod matrix table of correlations (n  167)*
GIT 2.0 PROMIS-GI
Trait Reﬂux Gas Diarrhea Constipation Incontinence Reﬂux Gas Diarrhea Constipation
GIT 2.0
Reﬂux 1.00
Gas 0.57 1.00
Diarrhea 0.13 0.23 1.00
Constipation 0.34 0.22 0.14 1.00
Incontinence 0.10 0.14 0.38 0.12 1.00
PROMIS GI
Reﬂux 0.77† 0.44 0.13 0.25 0.03 1.00
Gas 0.46 0.73† 0.30 0.29 0.10 0.39 1.00
Diarrhea 0.25 0.25 0.65† 0.02 0.54 0.23 0.31 1.00
Constipation 0.37 0.32 0.05 0.76† 0.01 0.35 0.36 0.20 1.00
Incontinence 0.12 0.11 0.43 0.18 0.87† 0.06 0.11 0.61 0.06
* Average convergent validity correlation is 0.766. Average off-diagonal correlation is 0.225 (164 df). GIT 2.0  University of California, Los Angeles,
Scleroderma Clinical Trials Consortium Gastrointestinal Scale; PROMIS  Patient-Reported Outcomes Measurement Information System; GI 
gastrointestinal.
† Convergent correlation between the different constructs when the 2 instruments are compared.
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the GIT 2.0 reﬂux scale has a single item assessing solid
food dysphagia, as well as nausea and vomiting items.
This accounts for the relatively high correlations of the
reﬂux, disrupted swallowing, and nausea/vomiting scales
on the PROMIS GI symptom scales with the GIT 2.0 reﬂux
scale.
The average convergent validity correlation in the
MTMM was 0.77 and the average off-diagonal correlation
was 0.22 (Table 4). T-tests of the signiﬁcance of differences
between relevant corresponding correlations for evaluat-
ing discriminant validity showed that 39 of 40 hetero-
method (convergent correlations compared with correla-
tions among different constructs measured by different
methods) and 39 of 40 mono-method (convergent correla-
tions compared with correlations among the different con-
structs measured by the same method) comparisons were
statistically signiﬁcant in the hypothesized direction, pro-
viding strong support for construct validity.
DISCUSSION
GI involvement affects approximately 90% of SSc patients
(25) and the majority of patients have symptoms. Although
the preferred approach for evaluation of GI pathology is
tests such as endoscopy and manometry, it is impractical
to perform these tests in every patient, particularly as
symptoms evolve over time (2). PRO measures comple-
ment objective tests (8), and GI symptoms in SSc are in-
dependently associated with poor HRQOL (26).
The PROMIS GI scales assess symptoms that can be used
to assess the general population and patients with differ-
ent GI disorders. In the current study, PROMIS GI symp-
tom scales were compared to the widely used GIT 2.0 to
explore its construct validity in patients with SSc. Corre-
lations between PROMIS GI scales and corresponding GIT
2.0 scales were large, and correlations of scales measuring
different constructs were small, providing support for con-
struct validity.
The largest correlation between PROMIS GI scales and
corresponding GIT 2.0 scales was for fecal incontinence
(r  0.87), and this may be attributed to a single item that
is worded very similarly to GIT 2.0. A high correlation was
also noted between the PROMIS reﬂux, disrupted swal-
lowing, and nausea/vomiting scales and the GIT 2.0 reﬂux
scale (r  0.77, 0.61, and 0.66, respectively). This is likely,
as the GIT 2.0 does not have separate scales for disrupted
swallowing and nausea and vomiting; the reﬂux scale of
GIT 2.0 includes an item each for solid food dysphagia,
nausea, and vomiting. Solid and liquid dysphagia and
nausea/vomiting are common in patients in SSc due to
gastroesophageal reﬂux disease, esophageal dysmotility,
and gastroparesis (25,27–29). Hence, separate scales for
disrupted swallowing and nausea/vomiting are more
meaningful in patients with SSc. The correlations between
diarrhea and fecal incontinence scales for the 2 instru-
ments were also noteworthy (range 0.43–0.54). During our
qualitative phase for development of the PROMIS GI scale,
some patients stated that loose/frequent bowel movements
and fecal incontinence were in a continuum rather than
separate constructs. This is also supported by negative
correlations between fecal incontinence and constipation
scales (range 0.01 to 0.18).
PROMIS GI scales and GIT 2.0 demonstrated satisfactory
reliability (0.70 for all scales). The percentage of patients
with minimum and maximum scores can limit responsive-
ness to change in a longitudinal study. In our study,
PROMIS scales had lower percentage of patients in differ-
ent scales who achieved minimum and maximum scores
compared to GIT 2.0, suggesting that measurement preci-
sion may be better for the PROMIS bank over a wide range
compared to GIT 2.0. This will likely increase the ability
to detect true change and to fulﬁll power and sample size
requirements (30,31).
Our study has several strengths. First, it provides sup-
port for the PROMIS GI symptom scales in patients with
SSc. Second, it adds to the limited repertoire of psycho-
metrically sound instruments to assess the GI burden of
SSc. In clinical practice and trials, incorporation of ei-
ther GIT 2.0 or PROMIS GI scales is appropriate. Third,
PROMIS GI has advantage of separate scales for disrupted
swallowing and nausea/vomiting (applicable in SSc) and
will have data available on the same metric that allow
comparison of prevalence/severity of symptoms in pa-
tients with SSc with the general population and other GI
disorders, such as inﬂammatory bowel disease and irrita-
ble bowel disorder. On the other hand, PROMIS GI scales
require a computer to calculate the scores, whereas GIT 2.0
can be scored in the ofﬁce setting.
The study is not without limitations. First, the GIT 2.0
was one of the “legacy” instruments used during the de-
velopment of GI symptom item banks. Although there
are other measures to assess GI involvement in SSc, none
have been comprehensively evaluated as GIT 2.0 (2). Sec-
ond, the study population was quite homogenous, pre-
dominantly involving women (91%), mainly whites, and
patients who were highly educated (63% with graduate
degree). Larger studies in SSc and other GI disorders will
need to be conducted to assess responsiveness to change of
PROMIS GI item bank versus other “legacy” instruments.
In conclusion, this study provides support for the con-
struct validity of the PROMIS GI symptom item scales in
patients with SSc. These items are ready for use in clinical
practice to assess the presence and severity of GI symptoms.
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